This study demonstrates that a tryptophan-aspartic acid peptide analog inhibits membrane fusion, suggesting new antiviral strategies.
Membrane fusion is a crucial step in the infection cycle of an enveloped virus, and the development of fusion inhibitors could lead to broad-spectrum antivirals beyond the one-bug-one-drug paradigm. In our continued effort to design peptide-based fusion inhibitors that block fusion by modulating membrane physical properties rather than targeting viral proteins, we have designed a tryptophan-aspartic acid (WD)-containing peptide analog, mGG-21, from coronin 1. Coronin 1 has been implicated in preventing the fusion of live mycobacteria containing phagosomes with lysosomes. mGG-21 displays around 60% inhibition in fusion pore formation (complete fusion) in model membranes by likely increasing the acyl chain ordering of the membrane, regardless of the cholesterol content of the membrane, unlike its previously designed predecessors with 20–30% inhibition activity. Further, we show that mGG-21 inhibits Influenza and Chikungunya virus infection in cellular models without exerting any toxicity. Taken together, our findings underscore the importance of WD repeats in the design of broad-range viral fusion inhibitors.
No takes yet. Share an insight, caveat, or question.
Pandia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: